Skip to main content
JW LIFESCIENCE CORPORATION logo

JW LIFESCIENCE CORPORATION — Investor Relations & Filings

Ticker · 234080 ISIN · KR7234080000 KO Manufacturing
Open in API
Filings indexed 190 across all filing types
Latest filing 2021-03-26 Audit Report / Informat…
Country KR South Korea
Listing KO 234080

About JW LIFESCIENCE CORPORATION

https://www.jw-lifescience.co.kr/lifesc…

JW LIFESCIENCE CORPORATION is a specialized manufacturer focused on the development and production of infusion solutions. The company's product portfolio includes a comprehensive range of intravenous (IV) fluids, from basic solutions to advanced nutrient infusions containing essential components such as amino acids, lipids, proteins, vitamins, and minerals. A key area of innovation is the development of high-value-added products, including multi-chambered infusion solutions. The company operates world-class manufacturing facilities and maintains dedicated research and development centers to support its commitment to producing high-quality medical fluids for patient treatment.

Recent filings

Filing Released Lang Actions
사업보고서 (2020.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for JW Life Science (제이더블유생명과학) for the fiscal year 2020. It includes the independent auditor's report (삼정회계법인), consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. It is not an Annual Report (10-K) as it lacks the broader management discussion and analysis (MD&A) or business overview typically found in a full 10-K, and it is not an announcement (RPA) because it contains the full financial data and audit opinion. FY 2020
2021-03-26 Korean
[기재정정]사업보고서 (2020.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for JW Life Science, covering the fiscal year 2020 (Jan 1, 2020 to Dec 31, 2020). It contains detailed financial statements, management discussion and analysis (MDA), governance information, and auditor opinions. Although it includes a 'Correction Report' (정정신고) header at the beginning, the document itself is the full annual filing submitted to the Financial Supervisory Service (FSS) in Korea, which corresponds to the 10-K equivalent in the provided schema. FY 2020
2021-03-26 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details changes to the board of directors, specifically the reappointment of an outside director. According to the filing definitions, announcements regarding changes in the board of directors or senior management fall under the 'MANG' category.
2021-03-26 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, dividend declarations, and director appointments. This aligns perfectly with the definition of a Declaration of Voting Results (DVA).
2021-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from JW Life Science. It provides a summary of the audit opinion (which is 'qualified' due to scope limitation) and key financial data (assets, liabilities, profit/loss) for the fiscal year ending 2020-12-31. While it contains financial data, it is a specific regulatory disclosure regarding the receipt and submission of the audit report, which falls under the Audit Report/Information category. FY 2020
2021-03-25 Korean
기타경영사항(자율공시)
Audit Report / Information Classification · 95% confidence The document is a regulatory filing from JW Life Science regarding a delay in the submission of their audit report. It is a short, voluntary disclosure (자율공시) explaining why the audit report has not yet been filed as required by law. Since it is a notification regarding the status of a report rather than the audit report itself, and it does not fit into specific categories like M&A or dividends, it is classified as a general regulatory filing (RNS). FY 2020
2021-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.